Using liquid biopsy to assess gastric cancer prognosis
The Prognostic Performance of Liquid Biopsy in Peritoneal Lavage and Plasma of Patients With Locally Advanced Gastric Cancer (LIQUID Study)
This study is testing if a simple blood test can help predict how well people with advanced stomach cancer will do after treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Milan) |
| Trial ID | NCT04943406 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the prognostic significance of liquid biopsy in patients with locally advanced gastric cancer. It involves collecting circulating tumor DNA from peritoneal lavage and plasma samples at various stages, including before and after surgery. The goal is to determine the predictive power of these liquid biopsies on overall survival and disease-free survival in affected patients. The study will include patients with specific stages of gastric adenocarcinoma undergoing either staging laparoscopy or radical surgery.
Who should consider this trial
Good fit: Ideal candidates are patients with histologically confirmed locally advanced gastric adenocarcinoma who meet specific staging criteria.
Not a fit: Patients with distant metastases, previous chemotherapy for gastric adenocarcinoma, or other significant health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a non-invasive method to better predict patient outcomes in gastric cancer.
How similar studies have performed: Other studies utilizing liquid biopsy techniques have shown promise in various cancers, suggesting potential success for this approach in gastric cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically proven gastric or gastro-esophageal junction (GEJ -Siewert type II -III) adenocarcinoma * More than cT2 and/or N + (UICC 8th edition) * Written informed consent Exclusion Criteria: * Presence of ascites or distant metastases * Previous chemotherapy for gastric adenocarcinoma * Previous gastric surgery * Absolute contraindications to surgery * Concomitant malignancies or history of other malignancies in the previous 5 years (with exception of in situ cervical carcinoma, basal cell carcinoma, superficial bladder tumors are allowed if curatively treated).
Where this trial is running
Milan
- Fondazione IRCSS Istituto Nazionale dei Tumori — Milan, Italy (Recruiting)
Study contacts
- Principal investigator: Carlo Sposito, MD — Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Study coordinator: Carlo Sposito, MD
- Email: carlo.sposito@istitutotumori.it
- Phone: 02-2390-3496
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.